Published in Cancer Weekly, August 16th, 2005
"The synthetic compound NK109 shows antitumor effects against a number of human cancer cell lines. The mechanism of action is thought to involve the inhibition of DNA topoisomerase II," scientists in Japan reported.
"However, NK109 also exhibits potent antitumor activities against doxorubicin-, cisplatin- and etoposide-resistant human cell lines. This paper describes target validation of NK109 using biotinylated NK109 and a T7 phage library screening procedure," explained K. Morohashi and colleagues, Genome & Drug Research Center.
"Phage particles displaying...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.